SAN FRANCISCO—January 26,
2015—Invitae Corporation, a genetic information company, announced today
that it had reached a settlement with Myriad Genetics, Inc., the University of
Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC
Research and Development Limited Partnership, and Endorecherche, Inc. in their
patent dispute concerning Invitae’s genetic testing for the BRCA1, BRCA2 and
MUTYH genes (MDL Case No. 2:14-CV-02510; Civil Case No. 2:14-cv-00153-RJS (D.
Utah).)
The parties
agreed to dismiss with prejudice their claims and counterclaims against each
other in this action, that Invitae would be granted a covenant not to sue with
respect to the patents–in–suit, and that the parties would bear their own
costs. This settlement will resolve all pending litigation between Invitae and
the other parties.
About Invitae
Based in San Francisco, Invitae’s mission is to bring comprehensive genetic
information into mainstream medical practice to improve the quality of
healthcare for billions of people. Currently focused on hereditary cancers,
Invitae’s goal is to aggregate most of the world’s genetic tests into a single
service with higher quality, faster turnaround time and lower price than many
single-gene tests today. The company currently provides a single diagnostic
test comprising over 200 genes for a variety of genetic disorders associated
primarily with cancer, but also covering cardiology, hematology, neurology and
pediatrics.
Contact:
Katherine Stueland
pr@invitae.com
415.254.1233